Skip to main content

Maria Llorian Salvador

Institutions of which they are part

Main researcher
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Maria Llorian Salvador

Institutions of which they are part

Main researcher
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Projects

Terapia inmunomoduladora para la retinitis pigmentosa

IP: Maria Llorian Salvador
Collaborators: -
Funding agency: Fundación Lucha contra la Ceguera FUNDALUCE
Funding: 30000
Reference: FUNDALUCE/2024/LLORIAN
Duration: 12/09/2025 - 12/09/2027

Retinal and cognitive dysfunction in type 2 diabetes

IP: Rafael Simó Canonge
Collaborators: Maria Llorian Salvador, Miriam Izquierdo Sans
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 152348.46
Reference: 2022 BP 00067
Duration: 01/04/2024 - 31/03/2027

Topical administration of sitagliptin in experimental models of diabetic retinopathy and glaucoma: delving into mechanisms of action and changing the therapeutic positioning (“Sit@Retina”).

IP: Rafael Simó Canonge
Collaborators: Maria Llorian Salvador
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 321250
Reference: PID2022-138544OB-I00
Duration: 01/09/2023 - 31/08/2026

Ministerio de Ciencia

Diabetis i metabolisme

IP: Rafael Simó Canonge
Collaborators: Josep A Villena Delgado, Carles Zafon Llopis, Cristina Hernández Pascual, David Martinez Selva, Rosario Pardo Diaz, Angel Michael Ortiz Zúñiga, Andreea Ciudin Mihai, Fiorella Ximena Palmas Candia, Ana Maria Ortiz de Urbina Olive, Monica Sanchez Bartres, Lorena Ramos Pérez, Marc Rivas Agudo, Diabetis i metabolisme, Anna Casteras Román, Alejandra Planas Vilaseca, Betina Biagetti Biagetti, Judit Amigó Farran, Mercè Abad Martín, Marta Comas Martínez, Hugo Ramos Abellan, Rosa Burgos Peláez, David Sabater Martínez, Olga Simó Servat, Patricia Bogdanov Baruj, Maria Llorian Salvador, Enzamaría Fidilio Meli
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 60000
Reference: 2021 SGR 00655
Duration: 01/01/2022 - 30/06/2025

Related news

Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research

The work represents a paradigm shift in the clinical approach to this chronic, multifactorial disease, based on the clinical context of each patient and not only on weight loss.

The results of a phase 3 clinical trial show that orforglipron reduces body weight by an average of 11% and improves cardiovascular risk factors.

Related professionals

Gonzalo Ballesteros Reviriego

Gonzalo Ballesteros Reviriego

Main researcher
Research Group of Physical Medicine and Rehabilitation
Read more
Maria Antonia Arbos  Via

Maria Antonia Arbos Via

Main researcher
General Surgery
Read more
Jacques Planas Morin

Jacques Planas Morin

Biomedical Research in Urology
Read more
Lourdes Vendrell Bosch

Lourdes Vendrell Bosch

Senior researcher
Clinical Pharmacology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.